No-carrier-added radiosynthesis of [123I]HIPDM: N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-1,3-propanediamine

Add time:07/15/2019    Source:sciencedirect.com

The multi-millicurie production of the SPECT radiopharmaceutical N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-1,3-propanediamine ([123I]HIPDM) in high specific activity is described. Using no-carrier-added electrophilic iododeprotonation reactions and HPLC purification, [123I]HIPDM can be isolated in 70–76% radiochemical yield and specific activity >2000 Ci/mmol within an overall preparation time of 75 min. This methodology is readily adapted to the clinical setting, and eliminates the need for co-injection of macroscopic HIPDM in SPECT imaging procedures.

We also recommend Trading Suppliers and Manufacturers of N-(3-iodobenzyl)-1-piperidinesulfonamide (cas 890593-41-6). Pls Click Website Link as below: cas 890593-41-6 suppliers

Prev:The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis
Next:Spectroscopic, structural and anticancer activity studies of (−)-cytisine halogenated N-benzyl derivatives)